Original articles
Sara Abdelfatah, Angela Berg, Qi Huang, Li Jun Yang, Sami Hamdoun, Anette Klinger, Henry J. Greten, Edmond Fleischer, Thorsten Berg, Vincent K. W. Wong, Thomas Efferth. MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate[J]. Acta Pharmaceutica Sinica B, 2019, 9(5): 1021-1034

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate
Sara Abdelfataha, Angela Bergb, Qi Huangc, Li Jun Yangc, Sami Hamdouna, Anette Klingerd, Henry J. Gretene, Edmond Fleischerd, Thorsten Bergb, Vincent K. W. Wongc, Thomas Effertha
a Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz 55128, Germany;
b Leipzig University, Institute of Organic Chemistry, Leipzig 04103, Germany;
c State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China;
d MicroCombiChem GmbH, Wiesbaden 65203, Germany;
e Abel Salazar Institute of Biomedical Sciences, University of Porto, Porto 4099-003, Portugal
Abstract:
Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity. PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory function for kinase activity and substrate recognition. We report on 3-bromomethylbenzofuran-2-carboxylic acid ethyl ester (designated:MCC1019) as selective PLK1 inhibitor targeting PLK1 PBD. Cytotoxicity and fluorescence polarization-based screening were applied to a library of 1162 drug-like compounds to identify potential inhibitors of PLK1 PBD. The activity of compound MC1019 against the PLK1 PBD was confirmed using fluorescence polarization and microscale thermophoresis.This compound exerted specificity towards PLK1 over PLK2 and PLK3. MCC1019 showed cytotoxic activity in a panel of different cancer cell lines. Mechanistic investigations in A549 lung adenocarcinoma cells revealed that MCC1019 induced cell growth inhibition through inactivation of AKT signaling pathway, it also induced prolonged mitotic arrest-a phenomenon known as mitotic catastrophe, which is followed by immediate cell death via apoptosis and necroptosis. MCC1019 significantly inhibited tumor growth in vivo in a murine lung cancer model without affecting body weight or vital organ size, and reduced the growth of metastatic lesions in the lung. We propose MCC1019 as promising anti-cancer drug candidate.
Key words:    Polo-like kinase    PLK1    Polo box domain    Mono-targeted therapy    Cell cycle    Necroptosis    Spindle damage   
Received: 2018-08-23     Revised: 2018-12-20
DOI: 10.1016/j.apsb.2019.02.001
Funds: This work was partly supported by the Deutsche Forschungsgemeinschaft (DFG INST 268/281-1 FUGG and BE 4572/3-1, Germany). Sara Abdelfatah is grateful to the German Academic Exchange Service (DAAD) for a PhD stipend.
Corresponding author: Thomas Efferth     Email:efferth@uni-mainz.de
Author description:
Service
PDF(KB) Free
Print
0
Authors
Sara Abdelfatah
Angela Berg
Qi Huang
Li Jun Yang
Sami Hamdoun
Anette Klinger
Henry J. Greten
Edmond Fleischer
Thorsten Berg
Vincent K. W. Wong
Thomas Efferth

References:
1. Golsteyn RM, Schultz SJ, Bartek J, Ziemiecki A, Ried T, Nigg EA. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 1994;107:1509-17.
2. Nigg EA. Polo-like kinases:positive regulators of cell division from start to finish. Curr Opin Cell Biol 1998;10:776-83.
3. Jackman M, Lindon C, Niggt EA, Pines J. Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol 2003;5:143-8.
4. Descombes P, Nigg EA. The polo-like kinase Plx1 is required for M phase exit and destruction of mitotic regulators in Xenopus egg extracts. EMBO J 1998;17:1328-35.
5. Bosco A, Golsteyn RM. Emerging anti-mitotic activities and other bioactivities of sesquiterpene compounds upon human cells. Molecules 2017;22:459-48.
6. Sanhaji M, Ritter A, Belsham HR, Friel CT, Roth S, Louwen F, et al. Polo-like kinase 1 regulates the stability of the mitotic centromereassociated kinesin in mitosis. Oncotarget 2014;5:3130-44.
7. Weichert W, Ullrich A, Schmidt M, Gekeler V, Noske A, Niesporek S, et al. Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci 2006;97:271-6.
8. Li H, Wang H, Sun Z, Guo Q, Shi H, Jia Y. The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients:immunohistochemical analysis. Biosci Rep 2017;37:BSR20170852.
9. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009;14:559-70.
10. Mao Y, Xi L, Li Q, Cai Z, Lai Y, Zhang X, et al. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1. Oncol Rep 2016;36:49-56.
11. Hu K, Law JH, Fotovati A, Dunn SE. Small interfering RNA library screen identified polo-like kinase-1(PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Breast Cancer Res 2012;14:R22.
12. Seth S, Matsui Y, Fosnaugh K, Liu Y, Vaish N, Adami R, et al. RNAibased therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther 2011;19:928-35.
13. Matthess Y, Raab M, Knecht R, Becker S, Strebhardt K. Sequential Cdk1 and Plk1 phosphorylation of caspase-8 triggers apoptotic cell death during mitosis. Mol Oncol 2014;8:596-608.
14. Pujade-Lauraine E, Selle F, Weber B, Ray-Coquard IL, Vergote I, Sufliarsky J, et al. Volasertib versus chemotherapy in platinumresistant or-refractory ovarian cancer:a randomized phase Ⅱ groupe des investigateurs nationaux pour l'etude des cancers de l'ovaire study. J Clin Oncol 2016;34:706-13.
15. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009;15:3094-102.
16. Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, et al. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood 2014;124:1426-34.
17. Raab M, Pachl F, Kramer A, Kurunci-Csacsko E, Dotsch C, Knecht R, et al. Quantitative chemical proteomics reveals a Plk1 inhibitorcompromised cell death pathway in human cells. Cell Res 2014;24:1141-5.
18. Lowery DM, Lim D, Yaffe MB. Structure and function of Polo-like kinases. Oncogene 2005;24:248-59.
19. Jang Y-J, Lin C-Y, Ma S, Erikson RL. Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc Natl Acad Sci U S A 2002;99:1984-9.
20. García-Alvarez B, de Cárcer G, Ibañez S, Bragado-Nilsson E, Montoya G. Molecular and structural basis of polo-like kinase 1 substrate recognition:implications in centrosomal localization. Proc Natl Acad Sci U S A 2007;104:3107-12.
21. Liu F, Park J-E, Qian W-J, Lim D, Gräber M, Berg T, et al. Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat Chem Biol 2011;7:595-601.
22. Elia AEH, Rellos P, Haire LF, Chao JW, Ivins FJ, Hoepker K, et al. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 2003;115:83-95.
23. Berg A, Berg T. Inhibitors of the Polo-box domain of Polo-like kinase 1. ChemBioChem 2016;17:650-6.
24. Borra RC, Lotufo MA, Gagioti SM, Barros FDM, Andrade PM. A simple method to measure cell viability in proliferation and cytotoxicity assays. Braz Oral Res 2009;23:255-62.
25. Hamdoun S, Fleischer E, Klinger A, Efferth T. Lawsone derivatives target the Wnt/β-catenin signaling pathway in multidrug-resistant acute lymphoblastic leukemia cells. Biochem Pharmacol 2017;146:63-73.
26. Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T. Inhibition of Polo-like kinase 1 by blocking Polo-box domain-dependent protein-protein interactions. Chem Biol 2008;15:459-66.
27. Reindl W, Strebhardt K, Berg T. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Anal Biochem 2008;383:205-9.
28. Reindl W, Gräber M, Strebhardt K, Berg T. Development of highthroughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3. Anal Biochem 2009;395:189-94.
29. Jerabek-Willemsen M, Wienken CJ, Braun D, Baaske P, Duhr S. Molecular interaction studies using microscale thermophoresis. Assay Drug Dev Technol 2011;9:342-53.
30. Seo E-J, Efferth T. Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approach for differentiation therapy. Oncotarget 2016;7:16818-39.
31. Reulecke I, Lange G, Albrecht J, Klein R, Rarey M. Towards an integrated description of hydrogen bonding and dehydration:decreasing false positives in virtual screening with the HYDE scoring function. ChemMedChem 2008;3:885-97.
32. Law BYK, Qu YQ, Mok SWF, Liu H, Zeng W, Han Y, et al. New perspectives of cobalt tris(bipyridine) system:anti-cancer effect and its collateral sensitivity towards multidrug-resistant (MDR) cancers. Oncotarget 2017;8:55003-21.
33. Seidel SAI, Wienken CJ, Geissler S, Jerabek-Willemsen M, Duhr S, Reiter A, et al. Label-free microscale thermophoresis discriminates sites and affinity of protein-ligand binding. Angew Chem Int Ed Engl 2012;51:10656-9.
34. Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 2011;1813:1938-45.
35. Klotz LO, Sánchez-Ramos C, Prieto-Arroyo I, Urbánek P, Steinbrenner H, Monsalve M. Redox regulation of FoxO transcription factors. Redox Biol 2015;6:51-72.
36. Webb AE, Brunet A. FOXO transcription factors:key regulators of cellular quality control. Trends Biochem Sci 2014;39:159-69.
37. Harada H, Itasaka S, Kizaka-Kondoh S, Shibuya K, Morinibu A, Shinomiya K, et al. The Akt/mTOR pathway assures the synthesis of HIF-1α protein in a glucose-and reoxygenation-dependent manner in irradiated tumors. J Biol Chem 2009;284:5332-42.
38. Peters U, Cherian J, Kim JH, Kwok BH, Kapoor TM. Probing celldivision phenotype space and Polo-like kinase function using small molecules. Nat Chem Biol 2006;2:618-26.
39. Clay FJ, McEwen SJ, Bertoncello I, Wilks AF, Dunn AR. Identification and cloning of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila. Proc Natl Acad Sci U S A 1993;90:4882-6.
40. Syed N, Smith P, Sullivan A, Spender LC, Dyer M, Karran L, et al. Transcriptional silencing of Polo-like kinase 2(SNK/PLK2) is a frequent event in B-cell malignancies. Blood 2006;107:250-6.
41. Yang Y, Bai J, Shen R, Brown SAN, Komissarova E, Huang Y, et al. Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res 2008;68:4077-85.
42. Yin Z, Song Y, Rehse PH. Thymoquinone blocks pSer/pThr recognition by plk1 polo-box domain as a phosohate mimic. ACS Chem Biol 2013;8:303-8.
43. Zeino M, Saeed MEM, Kadioglu O, Efferth T. The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein-a well-known, yet poorly understood drug transporter. Invest New Drugs 2014;32:618-25.
44. Cai XP, Chen LD, Song H Bin, Zhang CX, Yuan ZW, Xiang ZX. PLK1 promotes epithelial-mesenchymal transition and metastasis of gastric carcinoma cells. Am J Transl Res 2016;8:4172-83.
45. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
46. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011;1813:1978-86.
47. Li CJ, Chang JK, Chou CH, Wang GJ, Ho ML. The PI3K/Akt/FOXO3a/p27Kip1 signaling contributes to anti-inflammatory drugsuppressed proliferation of human osteoblasts. Biochem Pharmacol 2010;79:926-37.
48. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001;13:167-71.
49. Masoud GN, Li W. HIF-1α pathway:role, regulation and intervention for cancer therapy. Acta Pharm Sin B 2015;5:378-89.
50. Kops GJPL, Weaver BAA, Cleveland DW. On the road to cancer:aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5:773-85.
51. Matsumura S, Toyoshima F, Nishida E. Polo-like kinase 1 facilitates chromosome alignment during prometaphase through BubR1. J Biol Chem 2007;282:15217-27.
52. Hunt T, Nasmyth K, Novak B. The cell cycle. Philos Trans R Soc B Biol Sci 2011;366:3494-7.
53. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001;410:215-20.
54. Toyoshima-Morimoto F, Taniguchi E, Nishida E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002;3:341-8.